---
title: "GLP-1 RAs on Top of Statins Linked to Lower Mortality, MI, and Stroke in ASCVD with Obesity"
id: "medrxiv-0-glp-1-receptor-agonists-added-to-statin-therapy-and-cardiovascular-outcomes-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-glp-1-receptor-agonists-added-to-statin-therapy-and-cardiovascular-outcomes-in"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1?rss=1"
published_at: "2026-11-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 RAs on Top of Statins Linked to Lower Mortality, MI, and Stroke in ASCVD with Obesity
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-glp-1-receptor-agonists-added-to-statin-therapy-and-cardiovascular-outcomes-in
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1?rss=1)
- **Published At:** 2026-11-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators used the TriNetX Research Network across 108 US healthcare organizations to identify patients with established **ASCVD** and body mass index ≥30 kg/m2 who were on **statins** and initiated **GLP-1 RAs** versus matched statin-only controls. - The source reported initial cohorts of 166,278 GLP-1 RA initiators and 920,176 statin-only controls before matching; propensity score matching on 34 covariates produced 119,911 matched pairs with 3-year follow-up. - Primary outcomes included all-cause mortality, myocardial infarction (MI), and ischemic stroke; the study team observed lower event rates among GLP-1 RA users for each endpoint during the 3-year window. - Reported point estimates: mortality 4.0% vs 7.5% (hazard ratio 0.479; 95% CI 0.463–0.496), MI HR 0.762 (95% CI 0.737–0.788), ischemic stroke HR 0.671 (95% CI 0.588–0.766); p-values reported as <0.001 for these comparisons. - Secondary analyses included a BMI ≥35 kg/m2 subgroup (62,385 pairs), four washout sensitivity analyses with 30–120 day windows, and a familial hypercholesterolemia (FH) exclusion analysis (161,312 matched pairs); benefits remained consistent across these analyses per the authors. - LDL response: the matched cohorts showed a higher proportion of GLP-1 RA users achieving **LDL <55 mg/dL** by risk analysis (17.1% vs 15.3%; RR 1.118; p<0.001), but the Kaplan-Meier time-to-event analysis for LDL target attainment was reported non-significant (HR 1.007; p=0.538). - The authors reported that IRB approval was not required because de-identified aggregate data were used. The preprint has not undergone peer review; authors declared no competing interests. - Data availability: data were obtained from TriNetX and are available from the corresponding author; the paper is a medRxiv preprint and should not guide clinical practice without peer review.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in ASCVD A Propensity Score-Matched Cohort Study Sunanda Tah, Michael Cheshire doi: https://doi.org/10.64898/2026.11.05.26367396 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Sunanda Tah West Virginia University School of Medicine * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sunanda%2BTah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tah%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASunanda%2BTah%2B) * For correspondence: sunandatah@gmail.com Michael Cheshire West Virginia University School of Medicine * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BCheshire%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cheshire%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichael%2BCheshire%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1339966/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1339966/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1339966/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1339966/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1339966/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objective: To evaluate whether GLP-1 RA use added to statins is associated with lower all-cause mortality, myocardial infarction (MI), and ischemic stroke versus statin monotherapy in ASCVD patients with body mass index (BMI) 30 kg/m2. Approach and Results:Using the TriNetX Research Network (108 U.S. healthcare organizations), we identified ASCVD patients with BMI 30 kg/m2 on statins initiating a GLP-1 RA (n=166,278) versus statin-only controls (n=920,176). Propensity score matching on 34 covariates yielded 119,911 matched pairs followed 3 years. Prespecified analyses included a BMI 35 subgroup (62,385 pairs), four washout sensitivity analyses (30-120 days), and a familial hypercholesterolemia exclusion analysis (161,312 matched pairs). Results. GLP-1 RA use was associated with significantly lower all-cause mortality (4.0% vs. 7.5%; HR 0.479; 95% CI: 0.463-0.496; p The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.05.26367368v1 "Challenges and Health Disparities in Prostate Cancer: Healthcare Access as a Driver of Inequities in a Rural Hospital Network")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.05.26367380v1 "Development and Preliminary Evaluation of a Brief Health Chatbot Acceptability Scale \(CAS\): A Pilot Study") Posted November 06, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/06/2026.11.05.26367396.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/06/2026.11.05.26367396.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in ASCVD A Propensity Score-Matched Cohort Study Sunanda Tah, Michael Cheshire medRxiv 2026.11.05.26367396; doi: https://doi.org/10.64898/2026.11.05.26367396 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367396v1%26text%3DGLP-1%2520Receptor%2520Agonists%2520Added%2520to%2520Statin%2520Therapy%2520and%2520Cardiovascular%2520Outcomes%2520in%2520ASCVD%2520A%2520Propensity%2520Score-Matched%2520Cohort%2520Study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367396v1%26t%3DGLP-1%2520Receptor%2520Agonists%2520Added%2520to%2520Statin%2520Therapy%2520and%2520Cardiovascular%2520Outcomes%2520in%2520ASCVD%2520A%2520Propensity%2520Score-Matched%2520Cohort%2520Study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367396v1%26title%3DGLP-1%2520Receptor%2520Agonists%2520Added%2520to%2520Statin%2520Therapy%2520and%2520Cardiovascular%2520Outcomes%2520in%2520ASCVD%2520A%2520Propensity%2520Score-Matched%2520Cohort%2520Study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367396v1%26title%3DGLP-1%2520Receptor%2520Agonists%2520Added%2520to%2520Statin%2520Therapy%2520and%2520Cardiovascular%2520Outcomes%2520in%2520ASCVD%2520A%2520Propensity%2520Score-Matched%2520Cohort%2520Study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.05.26367396) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.05.26367396v1&count=horizontal&via=&text=GLP-1%20Receptor%20Agonists%20Added%20to%20Statin%20Therapy%20and%20Cardiovascular%20Outcomes%20in%20ASCVD%20A%20Propensity%20Score-Matched%20Cohort%20Study&counturl=www.medrxiv.org/content/10.64898/2026.11.05.26367396v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (917) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (350) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5002) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (428) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (676) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1691) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16262) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1241) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7278) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (751) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1093) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5288) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1467) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1832) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1381) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16488) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1203) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (700) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (752) * [Neurology](https://www.medrxiv.org/collection/neurology) (7594) * [Nursing](https://www.medrxiv.org/collection/nursing) (377) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1130) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1296) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1040) * [Oncology](https://www.medrxiv.org/collection/oncology) (3744) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1093) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (409) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (465) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (501) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (143) * [Pathology](https://www.medrxiv.org/collection/pathology) (721) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1858) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (755) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (786) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6128) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9992) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2530) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1518) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1269) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (661) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (804) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (597) * [Surgery](https://www.medrxiv.org/collection/surgery) (803) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (109) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (319) * [Urology](https://www.medrxiv.org/collection/urology) (307) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Community reviews for this article: _There are no community reviews for this paper._ Automated Evaluations Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv. Automated Evaluations: _There are no automated evaluations for this paper._ Blog/Media Links medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Video medRxiv partners with conferences and institutions to display recordings of talks and seminars related to preprints. These are posted with the consent of the authors. Video: _There are no videos for this paper._ Powered by [![Hypothes.is logo](https://connect.biorxiv.org/eval/hypothesis.png)](https://web.hypothes.is/) Powered by [![Altmetric logo](https://connect.biorxiv.org/eval/altmetric.png)](https://www.altmetric.com/) ## Follow this preprint X You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the [medRxiv Alerts Page](https://medrxiv.org/alerts). Sign In to Follow this Preprint Email * Email this Articleclose Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following [GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in ASCVD A Propensity Score-Matched Cohort Study](https://www.medrxiv.org/content/10.64898/2026.11.05.26367396v1) Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Citation Toolsclose GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in ASCVD A Propensity Score-Matched Cohort Study Sunanda Tah, Michael Cheshire medRxiv 2026.11.05.26
## Related Clinical Research

- [Watchman cardiac implant: clinicians raise questions as Boston Scientific intensifies sales push](https://medichelpline.com/clinical-feed/stat-news-1-stat-doctors-have-questions-about-the-watchman-boston-scientific-has-a-sales.md)
- [Cardiovascular drug research after high-profile trial failures and safety alarms](https://medichelpline.com/clinical-feed/stat-news-6-the-future-of-heart-drug-research-in-the-wake-of-study-setbacks.md)
- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [GLP-1 Receptor Agonists Linked to Lower Mortality and Cardiovascular Events in T2D Patients with H](https://medichelpline.com/clinical-feed/medrxiv-18-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and-heart-failure-with.md)
- [Cardiovascular outcomes of GLP-1 receptor agonists: systematic review findings](https://medichelpline.com/clinical-feed/pubmed-42033237.md) (DOI: 10.1093/ajhp/zxag121)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.